Auris Medical Provides Update on Tinnitus Drug Development Strategy
25 avr. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, April 25, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Receives Positive Nasdaq Listing Determination
15 avr. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, April 15, 2019 (GLOBE NEWSWIRE) -- Hamilton, Bermuda, April 15, 2019 – Auris Medical Holding Ltd. (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics...
Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study
29 mars 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, March 29, 2019 - Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces 20-F Filing
14 mars 2019 21h48 HE
|
Auris Medical AG
Zug, Switzerland, March 15, 2019 (GLOBE NEWSWIRE) -- March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important...
Auris Medical Announces 20-F Filing
14 mars 2019 17h30 HE
|
Auris Medical AG
Zug, Switzerland, March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
14 mars 2019 07h00 HE
|
Auris Medical AG
Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability Intranasal betahistine program progressing towards proof-of-concept studies in...
Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal
11 mars 2019 08h50 HE
|
Auris Medical AG
Zug, Switzerland, March 11, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019
07 mars 2019 08h00 HE
|
Auris Medical AG
Zug, Switzerland, March 07, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Receipt of Nasdaq Notice
08 févr. 2019 17h00 HE
|
Auris Medical AG
Hearing Requested to Present Compliance Plan Zug, Switzerland, February 8, 2019 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that...
Auris Medical Announces Full Repayment of Hercules Loan Facility
01 févr. 2019 07h30 HE
|
Auris Medical AG
Zug, Switzerland, February 1, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...